Press Release Distribution

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for September 10, 2008 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   

Kenneth Blum, PhD, Resign's from Salugen, Inc. As Chief Scientific Officer and Vice Chairman of The Board Of Directors

All rights to intellectual property revoked from Salugen, Inc.
x-small text small text medium text large text

    /24-7PressRelease/ - SAN DIEGO, CA, September 10, 2008 Synaptamine, Inc. Kenneth Blum, PhD, a renowned neuroscientist credited with the co-discovery (with Dr. Ernest Noble of UCLA and former director of The National Institute on Alcoholism and Alcohol Abuse (NIAAA)) of the first genetic association of the dopamine D2 receptor gene with severe alcoholism, resigned from Salugen earlier this year due to the company's inability to perform. All other key executives of the company, with the exception of Brian Meshkin, CEO, also resigned. In accordance with Dr. Blum's agreement with Salugen, all rights to the intellectual property portfolio primarily owned by Dr. Blum and his research associates reverted to Dr. Blum, principal of Synaptamine, Inc. and other named patent holders. Key factors in the departure of the management team were not specifically disclosed however, under Mr. Meshkin's direction, Salugen was unable to raise capital, adequately perform operational activities or compensate employees and vendors.

The Blum Intellectual Property portfolio consisting of both nutrigenomic, nutrigenetic and pharmacogenomic concepts, including those related to Reward Deficiency Syndrome (RDS), a term first coined by Blum in 1995, and patents issued and pending thereof in the United States, Europe and other countries, immediately reverted to Dr. Blum, Synaptamine, Inc. and associates upon his resignation and written recognition of the breech of contractual obligations by Salugen and Mr. Meshkin. The loss of these rights negates any claims by Salugen, its successor companies or Mr. Meshkin to the resultant products in the Salugen product portfolio or any other current or future products incorporating patented concepts.

Press release service and press release distribution provided by

# # #

Contact Information:
Kenneth Blum
Synaptamine Inc

San Diego, ca
Voice: 6198902167
E-Mail: Email us Here
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.